Starton Therapeutics STAR-LLD Shows Promise in Multiple Myeloma Phase 1b Study
Starton Therapeutics presented positive Phase 1b data for STAR-LLD, a continuous low-dose lenalidomide therapy for relapsed/refractory multiple myeloma (MM),...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Starton Therapeutics presented positive Phase 1b data for STAR-LLD, a continuous low-dose lenalidomide therapy for relapsed/refractory multiple myeloma (MM),...
Olema Pharmaceuticals announced preclinical data for OP-3136, a KAT6 inhibitor, showing anti-tumor activity in ovarian, prostate, and non-small cell...
Harbinger Health presented new research at the American Association for Cancer Research (AACR) Annual Meeting showcasing advancements in their...
Zenflow, Inc. released three-year data from its ZEST pilot studies, demonstrating sustained positive outcomes for patients using the Zenflow...
Janssen-Cilag International NV announced promising interim results from the Phase 2b SunRISe-1 study (Cohort 4) of TAR-200, a gemcitabine-releasing...
Protara Therapeutics announced updated Phase 2 trial results for TARA-002, a cell-based therapy for Non-Muscle Invasive Bladder Cancer (NMIBC)....
Stablepharma Ltd. has initiated a Phase 1 clinical trial for its lead candidate, SPVX02, a fridge-free tetanus and diphtheria...
Foghorn Therapeutics announced preclinical data for several potential first-in-class cancer medicines, including FHD-909, a SMARCA2 inhibitor, and its selective...
Tenaya Therapeutics announced interim data from its RIDGE natural history study of adults with arrhythmogenic right ventricular cardiomyopathy (ARVC)...
Verana Health launched Qdata® Cataracts, a comprehensive dataset on cataract surgery outcomes derived from over 9 million de-identified patients...